COVID-19 vaccination in kidney transplant recipients.

Nat Rev Nephrol

Department of Transplantation Nephrology and Clinical Immunology Hospices Civils de Lyon, Claude Bernard Lyon I University, INSERM Unit 1111, Lyon, France.

Published: December 2021

Kidney transplant recipients receive therapeutic immunosuppression that impairs their immune responses to the COVID-19 mRNA vaccine. For this reason, this vulnerable patient population is insufficiently protected by the standard two-dose COVID-19 vaccination programme and requires a specific follow-up to guide personalization of an intensified vaccination approach.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475856PMC
http://dx.doi.org/10.1038/s41581-021-00491-7DOI Listing

Publication Analysis

Top Keywords

covid-19 vaccination
8
kidney transplant
8
transplant recipients
8
vaccination kidney
4
recipients kidney
4
recipients receive
4
receive therapeutic
4
therapeutic immunosuppression
4
immunosuppression impairs
4
impairs immune
4

Similar Publications

Apolipoprotein E (ApoE), especially the ApoE4 isotype, is suggested to influence the severity of respiratory viral infections; however, this association is still unclear. The presence of allele ε4 impacts the development of flu-like syndromes. This study aimed to evaluate the impact of the Apo E4 isoform on the severity and duration of flu-like syndromes, including the coronavirus disease COVID-19.

View Article and Find Full Text PDF

Immunological interventions, like vaccinations, are enabled by the predictive control of humoral responses to novel antigens. While the development trajectories for many broadly neutralizing antibodies (bnAbs) have been measured, it is less established how human subtype-specific antibodies develop from their precursors. In this work, we evaluated the retrospective development trajectories for eight anti-SARS-CoV-2 Spike human antibodies (Abs).

View Article and Find Full Text PDF

Unlabelled: Porcine deltacoronavirus (PDCoV) is an enteric pathogen that burdens the global pig industry and is a public health concern. The development of effective antiviral therapies is necessary for the prevention and control of PDCoV, yet to date, there are few studies on the therapeutic potential of PDCoV-neutralizing antibodies. Here, we investigate the therapeutic potential of a novel monoclonal antibody (mAb 4A6) which targets the PDCoV S1 protein and effectively neutralizes PDCoV, both pre- and post-attachment on cells, with IC50 values of 0.

View Article and Find Full Text PDF

Coronaviruses are characterized by their progeny assembly and budding in the endoplasmic reticulum-Golgi intermediate compartment (ERGIC). Our previous studies demonstrated that truncation of 9 amino acids in the cytoplasmic tail (CT) of the infectious bronchitis virus (IBV) spike (S) protein impairs its localization to the ERGIC, resulting in increased expression at the plasma membrane. However, the precise mechanism underlying this phenomenon remained elusive.

View Article and Find Full Text PDF

Background: Correct information is an essential tool to guide thoughts, attitudes, daily choices or more important decisions such as those regarding health. Today, a huge amount of information sources and media is available. Increasing possibilities of obtaining data also require understanding and positioning skills, particularly the ability to navigate the ocean of information and to choose what is best without becoming overwhelmed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!